SparkLabs Group operates a network of accelerators and venture capital funds, and today it is adding to them with the creation of a new global accelerator program focused on cybersecurity and blockchain-related startups in Washington, D.C.
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and Children’s National Health System, a pediatric academic medical center in Washington, have launched a clinical research partnership devoted to treating and preventing allergic, immunologic and infectious diseases in children. An inaugural symposium will take place at Children’s National on Sept. 17, 2018, to highlight the partnership and discuss current and future directions for its research activities.
Autolus Therapeutics is a promising clinical-stage biotech that is a leader in T-cell programming and manufacturing technology. They have seen rapid growth since launching in 2014, and recently executed a successful US IPO in June that raised $160.4M at a $17 share price and landed them on the Nasdaq (AUTL).
United Therapeutics Corporation announced that it has entered into an exclusive license agreement with privately held drug development company, Samumed LLC, for purchasing the North American rights to the latter’s IPF drug candidate, SM04646.
Principia Biopharma Inc. (Principia or the Company) (Nasdaq: PRNB), a clinical-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with significant unmet medical needs in immunology and oncology, today announced the closing of its initial public offering of 7,187,500 shares of its common stock, including the exercise in full of the underwriters’ option to purchase 937,500 additional shares of common stock, at a public offering price of $17.00 per share. The gross proceeds to Principia, before deducting underwriting discounts and commissions and offering expenses, were approximately $122.2 million. All of the common stock was offered by Principia. Principia’s common stock is listed on The Nasdaq Global Select Market under the trading symbol “PRNB.”
Galera Therapeutics, Inc., a clinical-stage biotechnology company focused on the development of drugs targeting oxygen metabolic pathways with the potential to transform cancer radiotherapy, today announced it has secured $150 million in a joint, oversubscribed Series C financing and royalty purchase agreement. The financing was led by new investor Clarus, with participation from additional new investors Adage Capital Management, HBM Healthcare Investments, Nan Fung Life Sciences, RA Capital, Rock Springs Capital and Tekla Capital Management LLC. Existing investors Correlation Ventures, Galera Angels, New Enterprise Associates, Novartis Venture Fund, Novo Ventures and Sofinnova Ventures also participated. In addition, Emmett T. Cunningham, Jr., M.D., Ph.D., MPH, Managing Director at Clarus, will join Galera’s Board of Directors.
The Maryland Tech Council (MTC), the state’s largest trade association supporting the technology and life sciences sectors, today announced the appointment of Marty Rosendale as Chief Executive Officer (CEO), effective immediately.
Host: UM BioPark & Wexford Science + Technology
Location: UMB BioPark On the Nook Cafe Patio 801 W. Baltimore Street Baltimore Maryland 21201
Time: 5:00pm to 6:30pm
Mingle with our honored guest, Alex Triantis, Dean of the Robert H. Smith School of Business, other members of the Smith School community, BioPark tenants, and UMB faculty & staff
Join one of the 24 Institutes and Centers within the NIH that awards extramural grants! Extramural grants account for approximately 80 percent of NIH’s budget and are awarded to investigators at more than 2,500 universities, medical schools, and other research organizations around the world. To learn more about the grants process, types of grant programs, and the peer review process, visit the website for the Office of Extramural Research.
It’s the 21st century and information is just right at the tip of our fingers – thanks to the wide, wide, internet world. However, in spite of all the availability of information and the easy access to it, many people are still under the cloak of hoaxes and myths – and the business world is no exemption.